CRL Stock Analysis: Buy, Sell, or Hold?
CRL - Charles River Laboratories International, Inc.
$161.10
1.94 (1.22%)
▲
5d:
+1.96%
30d:
-9.75%
90d:
-20.9%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When CRL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CRL trading at deep discount. Market pricing in -7.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: CRL trading at deep discount. Market pricing in -7.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$282.28
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$175.27
8.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRL is currently trading at $161.09, which is considered fair relative to its 30-day fair value range of $156.31 to $174.64. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.1) compared to its historical average (16.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CRL is in a downtrend. Immediate support is located at $149.63, while resistance sits at $168.24.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $199.07 (+25.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRL is in a downtrend. Immediate support is located at $149.63, while resistance sits at $168.24.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $199.07 (+25.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$156.31 -
$174.64
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.1% below Wall St target ($199.07)
Fair Price Analysis
30-Day Fair Range
$156.31 -
$174.64
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$10.05
(6.2%)
Support & Resistance Levels
Support Level
$149.64
Resistance Level
$168.24
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.05
Wall Street Target
$199.07
(+25.1%)
Revenue Growth (YoY)
-0.8%
Earnings Growth (YoY)
-17.3%
Profit Margin
-3.6%
Valuation Discount vs History
-7.6% cheaper
PE vs Historical
13.1 vs 16.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.6%
(market-implied from PE analysis)
1-Year Target
$147.06
(-8%)
2-Year Target
$135.89
(-15%)
3-Year Target
$125.56
(-21%)
3-Yr Target (if PE normalizes)
(PE: 13→17)
$159.66
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 9.8%)
$361.84
(+127%)
Base:
(SPY PE: 13.1, Growth: 9.8%)
$210.87
(+33%)
Bear:
(PE: 11.1, Growth: 9.8%)
$179.24
(+13%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.1 to 16.6
Stabilization Target:
$202.39
(+27.2%)
PE Expansion Potential:
+27.2%
Share & Embed Analysis
Last updated: March 30, 2026 1:49 PM ET
Data refreshes hourly during market hours. Next update: 2:49 PM
Data refreshes hourly during market hours. Next update: 2:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-02-05
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 60 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 61 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 54 HOLD |
